Search results for "clinical research"

showing 10 items of 474 documents

Acute Hormonal and Force Responses to Combined Strength and Endurance Loadings in Men and Women: The “Order Effect”

2013

Purpose To examine acute responses and recovery of serum hormones and muscle force following combined strength (S) and endurance (E) loading sessions in which the order of exercises is reversed (ES vs. SE). Methods This cross-over study design included recreationally endurance trained men and women (age 21–45 years, n = 12 men n = 10 women) who performed both loadings. Maximal bilateral isometric strength (MVC), isometric rate of force development (RFD) and serum concentrations of testosterone (T), cortisol (C), growth hormone (GH), insulin-like growth factor 1 (IGF-1), binding protein 3 (IGFBP3) and sex hormone binding globulin (SHBG) were measured during and after both loadings. Results B…

AdultMalemedicine.medical_specialtyendocrineAnatomy and PhysiologyStrength trainingClinical Research DesignIGFBP3lcsh:MedicineEndocrine SystemIsometric exerciseYoung AdultSex hormone-binding globulinEndocrinologyInternal medicinemedicineHumansMuscle StrengthSports and Exercise Medicinelcsh:ScienceBiologyMusculoskeletal SystemTestosteroneHydrocortisoneMultidisciplinarySurvey ResearchCross-Over StudiesbiologyEndocrine Physiologybusiness.industrylcsh:Rconcurrent strength and endurance trainingMiddle AgedCrossover studyhormonitHormonesEndocrinologyCross-Sectional Studiesbiology.proteinBody CompositionPhysical EnduranceMedicinelcsh:QFemaleneuromuscularbusinessHormonemedicine.drugResearch ArticlePLoS ONE
researchProduct

5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: A multicenter randomised phase II study of the Souther…

2000

The combination regimen CPT-11 plus bolus and infusion 5-fluorouracil (5-FU) with high-dose leucovorin (hybrid regimen LV5FU2) has been tested for activity and toxicity against advanced colorectal carcinoma in a randomised, multicenter phase II trial.A total of 102 chemotherapy-naïve patients were randomised in a 1:2 fashion to receive: leucovorin 100 mg/m2 administered as a two-hour infusion before 5-FU 400 mg/m2 as an intravenous bolus, and FU 600 mg/m2 as a 22-hour infusion immediately after 5-FU bolus injection repeated on days 1 and 2 (LV5FU2 regimen, arm A, 34 patients) or CPT-11 at 180 mg/m2 (150 mg/m2 for patients of ageor = 70 and75 years) only on day 1 immediately before LV5FU2 th…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentLeucovorinPhases of clinical researchIrinotecanGastroenterologyDisease-Free SurvivalFolinic acidBolus (medicine)Internal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions IntravenousAgedChemotherapybusiness.industryHematologyMiddle AgedChemotherapy regimenSurgeryIrinotecanRegimenTreatment OutcomeOncologyFluorouracilInjections IntravenousCamptothecinFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia…

2006

Background The aim of the study was to test the clinical efficacy and toxicity profile of gemcitabine (GEM) in combination with cisplatin (CDDP) in a series of patients affected by unresectable and/or metastatic biliary tree carcinoma (BTC) previously untreated with chemotherapy. Patients and methods Overall 38 consecutive patients who satisfied eligibility criteria (10 with gall-bladder carcinoma and 28 with bile duct carcinoma) were included in this phase II study. Median age was 61 years with median PS 1. Treatment included GEM 1000 mg/m2/week as 30 min i.v. on days 1 and 8, and CDDP 75–80 mg/m2 on day 1 with adequate hydration protocol and forced diuresis. Treatment was repeated every 3…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentPhases of clinical researchNeutropeniaDeoxycytidineGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansAgedChemotherapybusiness.industryHematologyMiddle Agedmedicine.diseaseGemcitabineGemcitabineSurgeryRegimenBile Duct NeoplasmsOncologyToxicityFemaleGallbladder NeoplasmsCisplatinbusinessProgressive diseasemedicine.drugAnnals of Oncology
researchProduct

Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a mu…

1995

Summary Purpose Vinorelbine has been demonstrated to be active against squamous cell carcinomas of the headneck (SCHNC) and lung. This multicenter phase II trial was carried out to evaluate the activity and tolerability of the combination of vinorelbine, cisplatin, and 5-fluorouracil given on an outpatient schedule in a series of 80 patients with recurrent SCHNC. Patients and methods Eighty patients with recurrent and/ or metastatic SCHNC were treated with a combination of CDDP 80 mg/m2 on day 1, 5-FU 600 mg/m2 as a 4-hour infusion on days 2-5, and vinorelbine 25 mg/m2 on days 2 + 8. This cycle was repeated every 28 days. Most patients had oral cavity, larynx, or oropharynx carcinoma (88%).…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentPhases of clinical researchVinorelbineVinblastineGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansNeoplasm MetastasisAgedChemotherapybusiness.industryVinorelbineHematologyMiddle Agedmedicine.diseaseSurgeryRegimenOncologyEpidermoid carcinomaTolerabilityFluorouracilHead and Neck NeoplasmsCarcinoma Squamous CellFemaleFluorouracilCisplatinNeoplasm Recurrence Localbusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas.

1998

Summary Background Ifosfamide has important activity in pretreated soft tissue sarcomas (STS), and recent data support a clinically significant dose-response relationship for this agent. Administration by continuous infusion and hematopoietic support have rendered dose intensification regimens possible by reducing both hematologic and non-hematologic toxicities. The optimal dose and schedule of ifosfamide when given at high doses remain to be defined. In a previous phase I study, we demonstrated the feasibility of a continuous infusion (c.i.) high-dose ifosfamide (HDI) regimen in the ambulatory setting for patients with advanced solid tumors. The objective of the present phase II study was …

AdultMalemedicine.medical_specialtymedicine.medical_treatmentUrologyPhases of clinical researchSoft Tissue NeoplasmsNeutropeniaDrug Administration Schedulechemistry.chemical_compoundGranulocyte Colony-Stimulating FactormedicineHumansIfosfamideInfusions IntravenousAntineoplastic Agents AlkylatingMesnaAgedMesnaChemotherapyIfosfamidebusiness.industrySarcomaHematologyMiddle Agedmedicine.diseaseChemotherapy regimenNitrogen mustardSurgeryRegimenTreatment OutcomeOncologychemistryFemalebusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Erratum: Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer

2005

Hormonal therapy is the preferred systemic treatment for recurrent or metastatic, post-menopausal hormone-receptor-positive breast cancer. Previous studies have shown that there is no cross-resistance between exemestane and reversible aromatase inhibitors. Exposure to hormonal therapy does not hamper later response to chemotherapy. Patients with locally advanced or metastatic, hormonal receptor positive or unknown, breast cancer were treated with oral anastrozole, until disease progression, followed by oral exemestane until new evidence of disease progression. The primary end point of the study was clinical benefit, defined as the sum of complete responses (CR), partial responses (PR) and >…

AdultOncologyCancer Researchmedicine.medical_specialtyNeoplasms Hormone-DependentAntineoplastic Agents Hormonalmedicine.medical_treatmentAdministration OralPhases of clinical researchAnastrozoleBreast NeoplasmsAnastrozoleMetastasischemistry.chemical_compoundbreast cancerBreast cancerExemestaneInternal medicineAntineoplastic Combined Chemotherapy ProtocolsNitrilesClinical StudiesHumansMedicineAgedGynecologybusiness.industrysequential hormonal therapyCancerMiddle AgedTriazolesmedicine.diseaseMetastatic breast cancerAndrostadienesOncologychemistryChemotherapy AdjuvantHormonal therapyFemaleHormone therapyCorrigendumbusinessmedicine.drugBritish Journal of Cancer
researchProduct

A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma

2006

We carried out a phase II nonrandomized study to examine the level of activity of oxaliplatin, pegylated liposomal doxorubicin, and cyclophosphamide in a patient population with relapsed ovarian cancer pretreated with platinum derivatives and paclitaxel. Patients received oxaliplatin (85 mg/m2), pegylated liposomal doxorubicin (30 mg/m2), and cyclophosphamide (750 mg/m2). A total of 49 patients (39 assessable for toxicity and response) were enrolled in this trial. Neutropenia grade 3 was observed in six patients (15%) and anemia grade 3 in one patient (0.2%). Fatigue grade 1–2 occurred in 26 patients (66%), nausea/vomiting grade 1 in 23 patients (58%), and alopecia grade 1–2 in 19 patients …

AdultOncologyTRIAL COMPARING CISPLATINmedicine.medical_specialtysecond-line therapy PLATINUM-BASED CHEMOTHERAPYOrganoplatinum CompoundsCyclophosphamidemedicine.medical_treatmentPhases of clinical researchAdenocarcinomaNeutropeniaPACLITAXELchemotherapyGastroenterologySINGLE-AGENTPolyethylene GlycolsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineEVALUATETOPOTECANCOMBINATIONCyclophosphamideAgedOvarian NeoplasmsChemotherapybusiness.industrySALVAGE CHEMOTHERAPYoxaliplatinObstetrics and GynecologyCombination chemotherapyMiddle Agedmedicine.diseaseSurvival AnalysisCANCEROxaliplatinRegimenliposomal doxorubicinovarian cancerOncologyDoxorubicinFemaleNeoplasm Recurrence LocalbusinessOvarian cancerFOLLOW-UPmedicine.drug
researchProduct

Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: A prospective phase II study of the Arbeitsgeme…

2007

Abstract Objective. A multicenter non-randomized phase II study was initiated to evaluate tolerability and efficacy of pegylated liposomal doxorubicin (PLD) in combination with carboplatin in gynecologic malignancies. Methods. One hundred forty women with recurrent or advanced endometrial ( n =31), cervical or vaginal cancer ( n =31), uterine sarcomas ( n =11), or recurrent platinum-sensitive ovarian cancer ( n =67) received six courses of PLD 40 mg/m 2 and carboplatin (AUC 6) every 28 days. Results. Hematological toxicities with NCI-CTC grade 3/4 were anemia in 8%, thrombocytopenia in 14%, neutropenia in 24%, and febrile neutropenia in 2% of 652 cycles. Grade 3/4 non-hematological toxiciti…

AdultOncologymedicine.medical_specialtyGenital Neoplasms FemalePhases of clinical researchNeutropeniaGastroenterologyDrug Administration ScheduleCarboplatinPolyethylene Glycolschemistry.chemical_compoundInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesInfusions IntravenousAgedAged 80 and overVaginal cancerUterine sarcomabusiness.industryEndometrial cancerObstetrics and GynecologyMiddle Agedmedicine.diseaseCarboplatinOncologychemistryDoxorubicinFemaleOvarian cancerbusinessFebrile neutropeniaGynecologic Oncology
researchProduct

Blunted cortisol response to stress in patients with eating disorders: Its association to bulimic features

2017

ObjectiveClinical research on cortisol response to stress in patients with eating disorders has provided controversial and even contradictory results. As this might be the consequence of the inclusion in the studies of heterogeneous clinical populations, 3 highly selected samples were studied. MethodsDexamethasone suppression test was performed on 15 restricting anorexia nervosa patients without history of bulimia nervosa (BN), 17 BN patients with normal weight and no history of anorexia nervosa, and 22 healthy controls. Three days later, the Trier Social Stress Test was applied, and 8 saliva samples were collected along the trial for cortisol assessment. ResultsWhen the patients were consi…

AdultSalivaAnorexia NervosaHydrocortisoneTrier Social Stress TestPhysiologyeating disorderscortisol03 medical and health sciencesstress0302 clinical medicinemental disordersmedicineTrier social stress testHumansBulimiaBulimia NervosaSalivaAssociation (psychology)business.industryBulimia nervosahypothalamus-pituitary-adrenal axismedicine.disease030227 psychiatryPsychiatry and Mental healthClinical PsychologyEating disordersClinical researchAnorexia nervosa (differential diagnoses)Dexamethasone suppression testbusinessStress Psychological030217 neurology & neurosurgeryhormones hormone substitutes and hormone antagonists
researchProduct

Hepatogenic differentiation of human mesenchymal stem cells from adipose tissue in comparison with bone marrow mesenchymal stem cells

2006

AIM: To investigate and compare the hepatogenic transdifferentiation of adipose tissue-derived stem cells (ADSC) and bone marrow-derived mesenchymal stem cells (BMSC) in vitro. Transdifferentiation of BMSC into hepatic cells in vivo has been described. Adipose tissue represents an accessible source of ADSC, with similar characteristics to BMSC. METHODS: BMSCs were obtained from patients undergoing total hip arthroplasty and ADSC from human adipose tissue obtained from lipectomy. Cells were grown in medium containing 15% human serum. Cultures were serum deprived for 2 d before cultivating under similar pro-hepatogenic conditions to those of liver development using a 2-step protocol with sequ…

AdultTranscriptional ActivationPathologymedicine.medical_specialtyCellular differentiationAdipose tissueBone Marrow CellsBiologyStem cell markerCytochrome P-450 Enzyme SystemClinical ResearchAlbuminsCell Line TumormedicineCytochrome P-450 CYP3AHumansCells CulturedAgedCCAAT-Enhancer-Binding Protein-betaRegeneration (biology)Mesenchymal stem cellTransdifferentiationGastroenterologyCell DifferentiationCytochrome P-450 CYP2E1Mesenchymal Stem CellsGeneral MedicineMiddle AgedPhenotypeAdipose TissueGene Expression RegulationHepatocyte Nuclear Factor 4HepatocytesHepatic stellate cellCancer researchThy-1 AntigensStem cellWorld Journal of Gastroenterology
researchProduct